Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

1st Optimal vs Medro

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
1st Optimal logo

1st Optimal

3.9
★★☆☆☆2/5

Best for: coaching bundled into the price rather than sold separately

Visit 1st Optimal
VS
Medro logo

Medro

6.8
★★★☆☆3.4/5

Best for: coverage in all 50 states, which most of the register will not confirm

Visit Medro

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, Medro starts at $199/mo, and Medro finishes ahead, 6.8 to 3.9. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

1st Optimal

Pricing not publicly listed.

Medro

MonthlyCompounded
$199/mo
semaglutide

Month-to-month; drops to $179/mo (3-month), $159/mo (6-month), or $149/mo (12-month). Illustrative — final price shown before checkout, may vary by dose/pharmacy/eligibility.

MonthlyCompounded
$299/mo
tirzepatide

Month-to-month; drops to $269/mo (3-month), $239/mo (6-month), or $224/mo (12-month). Illustrative — final price shown before checkout. Brand-name GLP-1 options also available if eligible.

What’s included

1st Optimal

Covered by the monthly price

Medication

Not stated

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

In the price

Medro

Covered by the monthly price

Medication

In the price

Clinician visits

Not stated

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

1st Optimal

3.9/10

Overall

Medro

6.8/10

Value25%

3.0A
vs
B
4.6

Effectiveness25%

5.0A
vs
B
10.0

User Experience15%

2.0A
vs
B
5.0

Trust & Safety15%

4.0A
vs
B
6.0

Accessibility10%

5.0A
vs
B
10.0

Support10%

5.0A
vs
B
4.5

Features & Coverage

Feature1st OptimalMedro
Starting Price$199/mo
Features8 features8 features
States AvailableNot disclosed50
Compounded✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

About 1st Optimal

Neither a monthly price nor a list of states is published. 1st Optimal operates out of Michigan across telehealth and functional medicine, writing the GLP-1s semaglutide and tirzepatide either as a weekly injection or as a daily oral tablet. Around the prescription it stacks at-home lab testing, interpretation of the blood work, coaching without limit and protocols built individually, all framed as long-term weight loss and longevity. Credentialed providers work virtually, treatment goes to the home, and nothing binds you to a long contract.

Read our full 1st Optimal review →

About Medro

Pricing is tiered by commitment and shown before checkout: semaglutide $149-$199/mo and tirzepatide $224-$299/mo, with free shipping and no membership. The final price can still vary by dose, pharmacy and eligibility. Medro Health Technologies, Inc. sells compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, through a partner medical group and licensed pharmacy partners in all 50 states. An online intake goes to a licensed provider who decides if treatment fits. LegitScript-certified.

Read our full Medro review →

Pros & Cons

1st Optimal

What we like

  • The monthly figure covers consult, shipping, coaching
  • No FDA warning letter matched this operator when we searched our enforcement register
  • A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
  • Baseline bloodwork is required before a prescription

Watch-outs

  • No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
  • No state list is on record here, so whether it serves your state cannot be confirmed from this page
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here

Medro

What we like

  • Semaglutide at $199 a month, within the normal band around this register's $189 median for the same drug and form
  • The monthly figure covers medication and shipping
  • Coverage is published for all 50 states
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Medro

Medro takes it, 6.8 against 3.9, and it is especially strong on coverage in all 50 states, which most of the register will not confirm. 1st Optimal is no weak second and may fit you better on coaching bundled into the price rather than sold separately.

Choose 1st Optimal if…

You want coaching bundled into the price rather than sold separately.

Choose Medro if…

You want coverage in all 50 states, which most of the register will not confirm and an opening price near $199 a month.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

YourEra

Semaglutide at $99/month, 63% under the register median

8.8

Gala

Moving between compounded and brand without changing seller

9.4

Trimi Health

Knowing which pharmacy fills the vial — it names VialsRx

1st Optimal vs Medro: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring 1st Optimal and Medro head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.